EA202092491A1 - Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение - Google Patents

Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение

Info

Publication number
EA202092491A1
EA202092491A1 EA202092491A EA202092491A EA202092491A1 EA 202092491 A1 EA202092491 A1 EA 202092491A1 EA 202092491 A EA202092491 A EA 202092491A EA 202092491 A EA202092491 A EA 202092491A EA 202092491 A1 EA202092491 A1 EA 202092491A1
Authority
EA
Eurasian Patent Office
Prior art keywords
growth factor
nerve growth
monoclonal antibody
chain variable
variable region
Prior art date
Application number
EA202092491A
Other languages
English (en)
Inventor
Чжунминь Максвелл Ван
Байюн Ли
Юй Ся
Пэн Чжан
Original Assignee
Акесо Байофарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акесо Байофарма, Инк. filed Critical Акесо Байофарма, Инк.
Publication of EA202092491A1 publication Critical patent/EA202092491A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к моноклональному антителу против фактора роста нервов, а также к кодирующему его гену и его применению. Моноклональное антитело против фактора роста нервов по настоящему изобретению содержит тяжелые цепи, содержащие константную область тяжелой цепи и вариабельную область тяжелой цепи, и легкие цепи, содержащие константную область легкой цепи и вариабельную область легкой цепи. Вариабельная область тяжелой цепи содержит три определяющие комплементарность области HCDR1, HCDR2 и HCDR3 и вариабельная область легкой цепи содержит три определяющие комплементарность области LCDR1, LCDR2 и LCDR3. Моноклональное антитело против фактора роста нервов по настоящему изобретению может специфически связываться с фактором роста нервов и может использоваться для обнаружения наличия и/или уровня фактора роста нервов, а также для производства лекарственного средства для ингибирования зависимой от фактора роста нервов пролиферации клеток TF-1 и для производства лекарственного средства для лечения или профилактики по меньшей мере одной из невропатической боли, хронической боли и связанной с воспалением боли, таким образом оно имеет хорошие перспективы применения и востребовано на рынке.
EA202092491A 2018-04-17 2019-04-10 Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение EA202092491A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810344670.3A CN108623687A (zh) 2018-04-17 2018-04-17 神经生长因子的单克隆抗体及其编码基因和应用
CN201811320006.1A CN109553683A (zh) 2018-04-17 2018-11-07 神经生长因子的单克隆抗体及其编码基因和应用
PCT/CN2019/082107 WO2019201133A1 (zh) 2018-04-17 2019-04-10 神经生长因子的单克隆抗体及其编码基因和应用

Publications (1)

Publication Number Publication Date
EA202092491A1 true EA202092491A1 (ru) 2021-02-09

Family

ID=63705267

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092491A EA202092491A1 (ru) 2018-04-17 2019-04-10 Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение

Country Status (15)

Country Link
US (2) US11680095B2 (ru)
EP (1) EP3783021A4 (ru)
JP (1) JP2021521881A (ru)
KR (1) KR20200143471A (ru)
CN (3) CN108623687A (ru)
AU (1) AU2019254934A1 (ru)
BR (1) BR112020021256A2 (ru)
CA (1) CA3097414A1 (ru)
EA (1) EA202092491A1 (ru)
IL (1) IL277982A (ru)
MX (1) MX2020010863A (ru)
PH (1) PH12020551678A1 (ru)
SG (1) SG11202010150PA (ru)
WO (1) WO2019201133A1 (ru)
ZA (1) ZA202006317B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
CN110684106B (zh) * 2019-09-30 2021-02-02 达石药业(广东)有限公司 一种靶向神经生长因子的单克隆抗体及其应用
CN117003868B (zh) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117050175A (zh) * 2020-04-17 2023-11-14 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
US20230220057A1 (en) * 2020-05-27 2023-07-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
CN114470189B (zh) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Ngf抗体在cipn性疼痛中的应用
CN113444176B (zh) * 2021-06-02 2022-10-14 武汉人福创新药物研发中心有限公司 Ngf的抗体及其应用
US20240018481A1 (en) 2021-07-30 2024-01-18 Chengdu Unovel Biopharma Co., Ltd. Recombinant cho cell, construction method therefor, and detection system and method using same
CN116836276B (zh) * 2023-07-28 2023-12-08 艾可泰科(浙江)控股有限公司 一种用于修复膝关节损伤的干细胞制剂及其制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2921578C (en) * 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
AU2011201157C1 (en) * 2002-12-24 2017-09-07 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
DK1648509T3 (da) 2003-07-15 2013-01-07 Amgen Inc Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer
KR20060135060A (ko) 2004-04-07 2006-12-28 리나트 뉴로사이언스 코퍼레이션 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
AU2012201465A1 (en) * 2005-06-07 2012-04-05 Abbott Research B.V Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
EP2572729A3 (en) * 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
AR076650A1 (es) 2009-05-04 2011-06-29 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CN104910274B (zh) 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用

Also Published As

Publication number Publication date
AU2019254934A1 (en) 2020-11-19
US20210155683A1 (en) 2021-05-27
US20240025983A1 (en) 2024-01-25
BR112020021256A2 (pt) 2021-02-02
EP3783021A1 (en) 2021-02-24
CN112166121B (zh) 2022-11-22
IL277982A (en) 2020-11-30
WO2019201133A1 (zh) 2019-10-24
US11680095B2 (en) 2023-06-20
CA3097414A1 (en) 2019-10-24
PH12020551678A1 (en) 2021-06-07
JP2021521881A (ja) 2021-08-30
KR20200143471A (ko) 2020-12-23
CN108623687A (zh) 2018-10-09
CN109553683A (zh) 2019-04-02
MX2020010863A (es) 2021-01-29
EP3783021A4 (en) 2022-03-02
CN112166121A (zh) 2021-01-01
SG11202010150PA (en) 2020-11-27
ZA202006317B (en) 2024-01-31

Similar Documents

Publication Publication Date Title
EA202092491A1 (ru) Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
FI3110440T3 (fi) Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
EA035160B9 (ru) Антитела к st2 и их применение
NZ586053A (en) Anti-vegf antibody compositions and methods
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
NZ723369A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
PE20141151A1 (es) Proteinas de union al antigeno cd27l
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
AR105978A1 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp) y métodos de uso de las moléculas